Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline

Alkermes plc (ALKS) announced an update on their ongoing clinical study.

The Brilliance NT1 Study 304 is a phase 3 trial run by Alkermes, Inc. to test ALKS 2680 in adults with narcolepsy type 1. It aims to show if the drug can cut daytime sleepiness and attacks of sudden muscle weakness compared with placebo, a key step before any potential approval and wider commercial use.

The study is testing ALKS 2680, also called Alixorexton, as a once daily oral tablet given over 12 weeks. It is designed to improve symptoms of narcolepsy type 1 and is compared head to head against a matching placebo tablet.

This is an interventional study where adults are randomly placed into one of three groups. Two groups receive different doses of ALKS 2680 and the third gets placebo, with all parties blinded so patients, doctors, and study staff do not know who is on which treatment.

The trial uses a parallel group design, meaning patients stay on their assigned treatment arm for the full 12 week period. The main goal is treatment focused, looking first at symptom relief rather than exploring long term outcomes or diagnostic tools.

The study was first submitted on 15 April 2026, marking the formal start of the phase 3 program in narcolepsy type 1. The listing was last updated on 13 May 2026, signaling recent activity and ongoing site set up or recruitment work.

Primary completion and final completion dates have not yet been posted, so investors should assume data readouts remain at least several quarters away. That timing will be key in shaping near term news flow for Alkermes and may influence how analysts model revenue ramps.

For Alkermes shares, ALKS 2680 represents a new shot at a commercial asset in a focused sleep disorder market. Positive results could lift long term growth expectations, support multiple expansion, and diversify beyond the firm’s current psychiatry and oncology related lines.

Competition remains active, with existing narcolepsy therapies and pipeline programs from other CNS focused firms already in play. Investors should watch how ALKS 2680 positions on safety, convenience, and symptom control, as even strong data may still face pricing and access pressures in a crowded field.

The trial is currently listed as recruiting, and the recent update confirms it remains active and progressing, with further details available on the ClinicalTrials portal.

To learn more about ALKS’s potential, visit the Alkermes plc drug pipeline page.